AI in Healthcare in 2026: Deployment Reality and What's Working
Healthcare AI has been the most-hyped and most-difficult-to-deploy category. Where it actually sits in 2026.
Healthcare AI has been one of the most-hyped and most-difficult-to-deploy AI categories. The structural challenges — regulatory complexity, clinician trust, EMR integration, reimbursement architecture — have produced slower adoption than initial projections. By 2026, specific use cases have reached real production scale; others remain aspirational.
I want to walk through where healthcare AI actually sits.
What’s actually deployed at scale#
Radiology AI — the most-mature category. Chest X-ray triage, CT triage, mammography screening, retinal screening all have substantial FDA/CE-cleared products with real clinical deployment.
Ambient clinical documentation — Nuance/Microsoft DAX, Suki, Abridge, Heidi Health, and the regional players. Materially the fastest-adopted recent healthcare AI category.
Pathology AI — increasingly approved and deployed.
Cardiology AI — particularly for ECG analysis.
Diabetic retinopathy screening — operational at scale.
Specific clinical decision support — drug interaction checking, sepsis prediction, deterioration warning.
Administrative AI — appointment scheduling, prior authorization, billing optimization.
What’s still emerging#
General-purpose clinical AI copilots — beyond ambient documentation, more comprehensive clinical AI is in early deployment.
Diagnostic AI in primary care — beyond imaging, broader diagnostic support is less deployed.
Drug discovery AI — substantial pharma deployment but the impact on approved drugs is still emerging.
Surgical AI — robotic surgery has AI augmentation; autonomous surgery is research.
The regulatory landscape#
Healthcare AI operates within the most-rigorous regulatory framework of any AI deployment:
FDA (US) — Software as Medical Device pathway, Pre-Cert program work.
EMA / EU MDR / IVDR — increasingly rigorous for AI medical devices.
EU AI Act — medical AI is high-risk with substantial obligations.
MHRA (UK) — separate post-Brexit pathway.
PMDA (Japan) — sectoral oversight (covered here).
Sectoral regulators globally with overlapping AI guidance.
The regulatory work for healthcare AI is substantial and specifically-skilled.
What’s actually working operationally#
The patterns that distinguish production deployments from pilots:
- Workflow integration — AI that fits clinician workflow gets adopted.
- Trust building through explainability and clinician engagement.
- EMR integration — without integration, deployment fails.
- Reimbursement alignment — particularly important in the US context.
- Sustained engineering investment — not just one-time deployment.
Where pdpspectra fits#
Our healthcare engineering work spans clinical AI deployment, EMR integration, and the regulatory architecture.
Related reading: the AI triage telehealth post, the India ABDM health stack post, and the voice AI clinical documentation post.
Healthcare AI requires substantial engineering and regulatory work. Talk to our team about your deployment.